Neuland Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹3482.1499
- Today's High:
- ₹3741.05
- Open Price:
- ₹3741.05
- 52W Low:
- ₹1182.2134
- 52W High:
- ₹4338
- Prev. Close:
- ₹3579.8999
- Volume:
- 1747
Company Statistics
- Market Cap.:
- ₹47.98 billion
- Book Value:
- 774.829
- Revenue TTM:
- ₹13.33 billion
- Operating Margin TTM:
- 22.36%
- Gross Profit TTM:
- ₹2.86 billion
- Profit Margin:
- 16.16%
- Return on Assets TTM:
- 9.73%
- Return on Equity TTM:
- 17.83%
Company Profile
Neuland Laboratories Limited had its IPO on under the ticker symbol NEULANDLAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Neuland Laboratories Limited has a staff strength of 1,554 employees.
Stock update
Shares of Neuland Laboratories Limited opened at ₹3741.05 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹3482.15 - ₹3741.05, and closed at ₹3505.1.
This is a -2.09% slip from the previous day's closing price.
A total volume of 1,747 shares were traded at the close of the day’s session.
In the last one week, shares of Neuland Laboratories Limited have slipped by -3.29%.
Neuland Laboratories Limited's Key Ratios
Neuland Laboratories Limited has a market cap of ₹47.98 billion, indicating a price to book ratio of 2.3504 and a price to sales ratio of 2.1141.
In the last 12-months Neuland Laboratories Limited’s revenue was ₹13.33 billion with a gross profit of ₹2.86 billion and an EBITDA of ₹3.48 billion. The EBITDA ratio measures Neuland Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neuland Laboratories Limited’s operating margin was 22.36% while its return on assets stood at 9.73% with a return of equity of 17.83%.
In Q2, Neuland Laboratories Limited’s quarterly earnings growth was a positive 520.7% while revenue growth was a positive 64.1%.
Neuland Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 25.974
- Trailing PE
- 22.2606
- PEG
Its diluted EPS in the last 12-months stands at ₹168.01 per share while it has a forward price to earnings multiple of 25.974 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neuland Laboratories Limited’s profitability.
Neuland Laboratories Limited stock is trading at a EV to sales ratio of 2.2975 and a EV to EBITDA ratio of 13.3799. Its price to sales ratio in the trailing 12-months stood at 2.1141.
Neuland Laboratories Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 5.96%.
Balance sheet and cash flow metrics
- Total Assets
- ₹15.80 billion
- Total Liabilities
- ₹4.39 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 5.96%
Neuland Laboratories Limited ended 2024 with ₹15.80 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹15.80 billion while shareholder equity stood at ₹9.94 billion.
Neuland Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹4.39 billion in other current liabilities, in common stock, ₹4.65 billion in retained earnings and ₹2.79 billion in goodwill. Its cash balance stood at ₹454.16 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹742.46 million.
Neuland Laboratories Limited’s total current assets stands at ₹7.61 billion while long-term investments were ₹0 and short-term investments were ₹207.17 million. Its net receivables were ₹3.62 billion compared to accounts payable of ₹1.71 billion and inventory worth ₹2.79 billion.
In 2024, Neuland Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Neuland Laboratories Limited paid ₹0.06 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹3505.1
- 52-Week High
- ₹4338
- 52-Week Low
- ₹1182.2134
- Analyst Target Price
- ₹
Neuland Laboratories Limited stock is currently trading at ₹3505.1 per share. It touched a 52-week high of ₹4338 and a 52-week low of ₹4338. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹3549.05 and 200-day moving average was ₹2382.85 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3963.3% of the company’s stock are held by insiders while 2420.2% are held by institutions.
Frequently Asked Questions About Neuland Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company’s APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.